Gilead details discovery of GS-4224, a potent PD-L1 inhibitor for cancer

Aug. 31, 2022

Gilead Sciences Inc. has disclosed the discovery and structure of the potent, oral small molecule programmed cell death 1 ligand 1 (PD-L1) inhibitor GS-4224 (evixapodlin).

BioWorld Science Conferences Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for July 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 18, 2025.

Biocon wins first FDA interchangeable label of Novolog biosimilar

BioWorld

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo...

Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

BioWorld

In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...